
Fixed-duration zanubrutinib, bendamustine, rituximab achieves high response rates for Waldenström macroglobulinemia in first report from phase 2 trial
CR/VGPR rates were also not impacted by the presence of CXCR4 or TP53 mutations, wrote the study’s lead author, Andrew P. Branagan, MD, PhD, of Mass General Brigham Cancer Institute in Boston.





